Difference between revisions of "Immune effector cells toxicity management"
Jump to navigation
Jump to search
m |
m |
||
| Line 9: | Line 9: | ||
|- | |- | ||
|} | |} | ||
| + | <big>'''The purpose of this page is to address the management of toxicity from BiTE and immune effector cell (IEC) therapy, notably CAR-T. There is a separate page for the management of immune checkpoint inhibitor (ICI) toxicities, [[Immunotherapy_toxicity_management|available here]].'''</big> | ||
{{TOC limit|limit=4}} | {{TOC limit|limit=4}} | ||
=Guidelines= | =Guidelines= | ||
| + | ==ASCO== | ||
| + | *'''2021:''' Santomasso et al. [https://doi.org/10.1200/jco.21.01992 Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline] | ||
==ASTCT== | ==ASTCT== | ||
*'''2019:''' Lee et al. [https://doi.org/10.1016/j.bbmt.2018.12.758 ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells] | *'''2019:''' Lee et al. [https://doi.org/10.1016/j.bbmt.2018.12.758 ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells] | ||
| + | ==EBMT/JACIE/EHA== | ||
| + | *'''2022:''' Hayden et al. [https://doi.org/10.1016/j.annonc.2021.12.003 Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)] | ||
=REMS programs= | =REMS programs= | ||
Revision as of 12:55, 17 February 2023
| Page co-editor | Page co-editor | ||
|---|---|---|---|
 |
Leyre Zubiri, MD, PhD Massachusetts General Hospital Boston, MA |
 |
Matthew Hadfield, DO Lifespan/Brown University Providence, RI |
The purpose of this page is to address the management of toxicity from BiTE and immune effector cell (IEC) therapy, notably CAR-T. There is a separate page for the management of immune checkpoint inhibitor (ICI) toxicities, available here.
Guidelines
ASCO
- 2021: Santomasso et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
ASTCT
- 2019: Lee et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells